Sebelipase alfa for treating lysosomal acid lipase deficiency that is not Wolman disease (terminated appraisal) (TA961)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 28 March 2024
Sebelipase alfa for treating Wolman disease (HST30)Product type:GuidanceProgramme:Highly specialised technologies guidancePublished: 10 January 2024
Evinacumab for treating homozygous familial hypercholesterolaemia in people aged 12 years and over [ID2704]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 11 September 2024
Olipudase alfa for treating Niemann-Pick disease types A and B [ID3913 ]Status:In developmentProgramme:Highly specialised technologies guidanceExpected publication date: TBC
Venglustat for treating gangliosidoses in people 2 years and over [ID6358]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC